Holen Sie sich die Stockscreener-App
9.71
7.65%
0.69
Handel nachbörslich:
9.71
Schlusskurs vom Vortag:
$9.02
Offen:
$9.23
24-Stunden-Volumen:
30,925
Relative Volume:
0.91
Marktkapitalisierung:
$39.28M
Einnahmen:
$147.75M
Nettoeinkommen (Verlust:
$-284.23M
KGV:
-3.314
EPS:
-2.93
Netto-Cashflow:
$-317.54M
1W Leistung:
+10.59%
1M Leistung:
+15.32%
6M Leistung:
+80.82%
1J Leistung:
-37.80%
1-Tages-Spanne:
$9.23
$9.75
1-Wochen-Bereich:
$8.725
$9.75
52-Wochen-Spanne:
$4.85
$21.94
Fibrogen Inc Stock (FGEN) Company Profile
Firmenname
Fibrogen Inc
Sektor
Branche
Telefon
415-978-1200
Adresse
350 BAY STREET, SAN FRANCISCO, CA
Vergleichen Sie FGEN mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
FGEN
Fibrogen Inc
|
9.71 | 36.49M | 147.75M | -284.23M | -317.54M | -2.93 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.15 | 118.84B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
812.27 | 81.61B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
422.50 | 53.69B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
822.94 | 49.49B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
176.00 | 37.34B | 447.02M | -1.18B | -906.14M | -6.1812 |
Fibrogen Inc Stock (FGEN) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2023-08-08 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2023-06-26 | Herabstufung | BofA Securities | Buy → Neutral |
| 2023-06-26 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2023-06-26 | Herabstufung | Stifel | Buy → Hold |
| 2023-06-26 | Herabstufung | William Blair | Outperform → Mkt Perform |
| 2023-06-02 | Hochstufung | Stifel | Hold → Buy |
| 2023-01-31 | Hochstufung | William Blair | Mkt Perform → Outperform |
| 2023-01-26 | Hochstufung | Raymond James | Mkt Perform → Outperform |
| 2023-01-05 | Hochstufung | BofA Securities | Neutral → Buy |
| 2021-09-22 | Herabstufung | Goldman | Neutral → Sell |
| 2021-08-20 | Hochstufung | Raymond James | Underperform → Mkt Perform |
| 2021-07-16 | Herabstufung | BofA Securities | Buy → Neutral |
| 2021-07-16 | Herabstufung | Stifel | Buy → Hold |
| 2021-04-07 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2021-04-07 | Herabstufung | Mizuho | Buy → Neutral |
| 2021-03-31 | Hochstufung | BofA Securities | Neutral → Buy |
| 2021-03-02 | Herabstufung | Jefferies | Buy → Hold |
| 2021-02-01 | Eingeleitet | H.C. Wainwright | Buy |
| 2020-10-26 | Eingeleitet | Raymond James | Underperform |
| 2020-07-10 | Fortgesetzt | Stifel | Buy |
| 2020-05-01 | Eingeleitet | Cowen | Market Perform |
| 2020-04-27 | Eingeleitet | BofA/Merrill | Neutral |
| 2019-05-29 | Fortgesetzt | Goldman | Neutral |
| 2019-05-10 | Herabstufung | William Blair | Outperform → Mkt Perform |
| 2019-04-12 | Eingeleitet | Piper Jaffray | Neutral |
| 2019-02-11 | Fortgesetzt | Stifel | Buy |
| 2018-12-19 | Hochstufung | Citigroup | Neutral → Buy |
| 2017-08-08 | Bestätigt | Leerink Partners | Outperform |
| 2017-08-08 | Bestätigt | Stifel | Buy |
| 2017-07-21 | Herabstufung | Goldman | Buy → Neutral |
| 2017-07-11 | Eingeleitet | Jefferies | Buy |
| 2016-02-11 | Hochstufung | Credit Suisse | Neutral → Outperform |
| 2016-01-21 | Eingeleitet | Credit Suisse | Neutral |
| 2015-12-04 | Eingeleitet | Citigroup | Buy |
| 2015-09-23 | Eingeleitet | Lake Street | Hold |
| 2015-07-29 | Eingeleitet | Citigroup | Buy |
| 2015-07-20 | Hochstufung | Goldman | Neutral → Buy |
| 2014-12-09 | Eingeleitet | Stifel | Buy |
Alle ansehen
Fibrogen Inc Aktie (FGEN) Neueste Nachrichten
FibroGen stock rises after announcing rebrand to Kyntra Bio By Investing.com - Investing.com South Africa
FibroGen rebrands as Kyntra Bio with new Nasdaq ticker KYNB By Investing.com - Investing.com Australia
FibroGen (FGEN) Transforms into Kyntra Bio with a New Focus - GuruFocus
FibroGen, Inc. Rebrands to Kyntra Bio, Targeting Oncology and Rare Disease Therapeutics with New Nasdaq Trading Symbol "KYNB" - Quiver Quantitative
FibroGen rebrands to Kyntra Bio - MarketScreener
Cancer and rare disease drug maker Kyntra Bio is born from FibroGen - Stock Titan
Quarterly Earnings: Is FibroGen Inc stock a buy before product launchesJuly 2025 Review & Weekly Momentum Picks - moha.gov.vn
FibroGen shares advance after roxadustat earns orphan drug status - MSN
How FibroGen Inc. stock reacts to inflationary pressuresSwing Trade & Real-Time Buy Zone Alerts - Улправда
Published on: 2025-12-20 23:42:14 - Улправда
Why FibroGen Inc. (1FG0) stock attracts HNW investorsRecession Risk & Reliable Breakout Stock Forecasts - Улправда
Why FibroGen Inc. stock is a must watch in 2025July 2025 Selloffs & Precise Buy Zone Identification - DonanımHaber
Is FibroGen Inc. stock a buy before product launchesJuly 2025 Price Swings & Weekly Stock Breakout Alerts - DonanımHaber
FibroGen Q3 2025 Earnings Preview - MSN
Published on: 2025-12-19 15:46:05 - Улправда
Will FibroGen Inc. stock outperform international peers2025 Market Trends & Safe Capital Preservation Plans - Улправда
Published on: 2025-12-18 12:26:14 - Улправда
Is FibroGen (NASDAQ:FGEN) A Risky Investment? - simplywall.st
FDA grants orphan drug designation to FibroGen’s roxadustat for MDS By Investing.com - Investing.com Nigeria
FDA grants orphan drug designation to FibroGen’s roxadustat for MDS - Investing.com India
FibroGen stock rises after roxadustat receives Orphan Drug Designation By Investing.com - Investing.com Nigeria
FibroGen stock rises after roxadustat receives Orphan Drug Designation - Investing.com India
FibroGen (FGEN) Gains FDA Orphan Drug Status for Roxadustat - GuruFocus
Roxadustat granted orphan drug designation for the treatment of myelodysplastic syndromes by the U.S. FDA - marketscreener.com
FibroGen Receives FDA Orphan Drug Designation for Roxadustat in Myelodysplastic Syndromes, Phase 3 Protocol Set for Q4 2025 Submission - Quiver Quantitative
Roxadustat Granted Orphan Drug Designation for the Treatment of Myelodysplastic Syndromes by the U.S. Food and Drug Administration - The Manila Times
Roxadustat Granted Orphan Drug Designation for the - GlobeNewswire
Market Review: Will FibroGen Inc stock keep outperforming rivals2025 Risk Factors & Breakout Confirmation Trade Signals - moha.gov.vn
FibroGen Investor Suit Dismissed Following $28.5 Million Deal - Bloomberg Law News
Can FibroGen Inc. (1FG0) stock deliver strong annual returnsSell Signal & AI Powered Market Entry Strategies - Newser
Will FibroGen Inc. (1FG0) stock outperform global peers2025 Valuation Update & Safe Capital Growth Stock Tips - Newser
FibroGen (FGEN) Stock Analysis Report | Financials & Insights - Benzinga
Is FibroGen Inc. (1FG0) stock overpriced at current multiplesDividend Hike & Weekly Momentum Picks - Newser
How FibroGen Inc. (1FG0) stock reacts to fiscal policiesWeekly Trade Review & Weekly Watchlist for Hot Stocks - Newser
How dovish Fed policy supports FibroGen Inc. (1FG0) stockAnalyst Downgrade & Entry and Exit Point Strategies - Newser
How supply shortages influence FibroGen Inc. (1FG0) stockSell Signal & Weekly Return Optimization Alerts - Newser
Is FibroGen Inc. (1FG0) stock a top hedge fund pick2025 Fundamental Recap & Smart Allocation Stock Tips - Newser
FibroGen, Inc. to Present at Oppenheimer Movers in Rare Disease Summit on December 11, 2025 - Quiver Quantitative
FibroGen to Present at the Oppenheimer Movers in Rare Disease Summit - GlobeNewswire
Why FibroGen Inc. (1FG0) stock is trending on social mediaJuly 2025 PreEarnings & AI Enhanced Execution Alerts - moha.gov.vn
FibroGen started at buy by H.C. Wainwright - MSN
Finanzdaten der Fibrogen Inc-Aktie (FGEN)
Umsatz
Nettogewinn
Free Cashflow
ENV
Fibrogen Inc-Aktie (FGEN) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Wettig Thane | CEO |
Nov 13 '25 |
Buy |
9.18 |
1,000 |
9,180 |
22,239 |
| Schoeneck James A | Director |
Jun 30 '25 |
Buy |
5.07 |
23,567 |
119,485 |
39,666 |
| Wettig Thane | CEO |
Mar 24 '25 |
Buy |
0.35 |
145,000 |
50,663 |
543,329 |
| Schoeneck James A | Director |
Mar 20 '25 |
Buy |
0.35 |
250,000 |
88,000 |
323,722 |
| Schoeneck James A | Director |
Mar 21 '25 |
Buy |
0.34 |
50,000 |
17,040 |
373,722 |
28.63%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):